109 limits were recorded while the sweep ran, and they are printed here as recorded rather than summarized. Four of the 17 reviews were cut off by the retrieval limit before their tables ended, one evidence table refused retrieval altogether and is named rather than dropped, and two reviews contradict themselves on individual herbs — recorded here, not resolved.
| Class | Limit, as recorded |
| Anticoagulants and antiplatelets | Table 3 (possible plant-warfarin interactions) was truncated at 100,000 of 128,599 characters on the first pass. CLOSED: a completion pass read characters 100,000-128,599 and all 26 Table 3 rows sit in that remainder; they are published above. The per-row study identifiers behind Table 3's caption remain unenumerated. |
| Antidepressants, MAOIs and serotonergic drugs | clinician.com evidence-based herb-drug table refused retrieval (client_error) — named, not omitted |
| Antidepressants, MAOIs and serotonergic drugs | Retrieval was truncated at 100,000 of 241,705 characters on the first pass. CLOSED, and this was the worst of the cutoffs: characters 100,000-200,000 are reference list, and the article's OWN class-assignment tables sit at 200,000-241,705, so the original cutoff had severed them entirely. A completion pass read to the end of the article and recovered Table 1, published above as its own class. |
| Antidiabetic drugs | Retrieval was truncated at 100,000 of 174,041 characters on the first pass. CLOSED: a completion pass read the remainder, which is reference list and back matter only and added no botanical. One gap remains open and is not closed by that pass - the article references a Table 1 that was not served at either offset, so any herb appearing only in Table 1 is unmeasured. |
| Antihypertensives and blood-pressure drugs | Retrieval was truncated at 100,000 of 200,783 characters on the first pass. CLOSED: a completion pass read characters 100,000-200,783, which are the numbered reference list and site back matter with no review narrative and no table, and added no botanical. |
| Antihypertensives and blood-pressure drugs | hawthorn and pomegranate named in the introduction but their BP effects and interactions are not analyzed by the review, so they are NOT counted here |
| CYP450 enzymes and P-glycoprotein | Retrieval was truncated at 100,000 of 158,743 characters on the first pass, and the note that later tables may name further herbs assumed those tables lay in the unread half. CLOSED - and it closed by disproving that assumption rather than by confirming it. A completion pass read characters 100,000-158,743 and found reference entries and back matter only, no table. A further pass then measured where the tables actually are: all SEVEN sit inside the article's first 100,000 characters, the range the first pass had already read. Tables 1 and 2 carry no botanicals at all, describing CYP families and clinically relevant CYP polymorphisms; Tables 3 to 7 carry 31 distinct plant entries across 41 rows, of which 27 match this catalog and are published above as their own class. No table appears after character 100,000 and none is served only as a separate table sub-page, so the three refusing sub-page channels were never the obstacle they appeared to be, and the guess that further herbs lay behind them is withdrawn. What remains is not a retrieval gap but a quotation limit, recorded separately: the one channel that served this article refused verbatim cell-by-cell transcription, so cell prose is close paraphrase, while captions, column headers, row counts, plant names, isoforms, directions, evidence grades and the figures shown in quotation marks are read from the page. |
| CYP450 enzymes and P-glycoprotein | review is internally inconsistent for Danshen and Gan Cao (induction vs inhibition stated differently in text and tables) — recorded, not resolved here |
| Cardiac drugs, arrhythmia and QT prolongation | Retrieval was truncated at 100,000 of 241,705 characters on the first pass. CLOSED: the same completion pass recovered Table 2, the article's arrhythmia table, from characters 200,000-241,705, which the original cutoff had severed. It is published above as its own class and it names aconite, oleander, lily of the valley, kratom, yohimbe and evodia among others that the truncated pass could not see. |
| MSD Manual multi-class table | the source table's own Chromium row links to the Chamomile page, an inconsistency in the source recorded here rather than resolved |
| Sedatives CNS depressants and benzodiazepines | the review prints no herb count; the denominator 11 is the reviewer's own enumeration of the botanical genera it names, not a figure the review states |
| Sedatives CNS depressants and benzodiazepines | GROUP-LEVEL ATTRIBUTION, not herb-specific: the six caffeine-containing herbal drugs (tea, coffee, guarana, mate, cola, cocoa) share ONE table that does not break interactions down by herb, so those six rows carry the caffeine group finding and not a finding measured on the individual plant |
| Sedatives CNS depressants and benzodiazepines | evidence type is not labelled by the source for 10 of 11 botanicals; only hop is characterized, verbatim, as 'based mainly on experimental evidence' |
| Sedatives CNS depressants and benzodiazepines | source self-contradiction (valerian), recorded not resolved: the text states valerian 'does not affect the pharmacokinetics of caffeine, alprazolam, or midazolam to a clinically relevant extent' while its own table reports alprazolam plasma level up 19% |
| Sedatives CNS depressants and benzodiazepines | source self-contradiction (ginkgo), recorded not resolved: the text calls ginkgo a GABA-A antagonist while the table describes the same EGb 761 extract as a GABA-A agonist |
| Sedatives CNS depressants and benzodiazepines | source self-contradiction (hop), recorded not resolved: the section states no clinically significant interactions are reported in the EU herbal monograph while the hop table carries diazepam and phenobarbital rows reading additive effect, increased adverse reactions |
| Sedatives CNS depressants and benzodiazepines | direction split within this class: valerian and hop POTENTIATE, while St John's wort, cannabis and the caffeine herbs REDUCE sedative effect; ginkgo is printed in both directions |
| Sedatives CNS depressants and benzodiazepines | anesthesia coverage is thin: only valerian carries general-anesthetic rows; ginkgo's surgical caution is about bleeding, not anesthetic interaction |
| Sedatives CNS depressants and benzodiazepines | printed apparent typo reproduced as printed, not corrected: the caffeine hypnotics row gives the basis as CYP2C2, which is not a recognized CYP isoform |
| Sedatives CNS depressants and benzodiazepines | kava and chamomile are not covered by this review at all; passionflower, lemon balm and lavender are named only as components of sedative tea combinations with no interactions analyzed |
| Sedatives CNS depressants and benzodiazepines | clinician.com and pmc.ncbi.nlm.nih.gov refused retrieval (reCAPTCHA interstitial) and were named rather than mined |
| Sedatives CNS depressants and benzodiazepines | a second source, Pharmaceuticals 2026;19(3):399 doi:10.3390/ph19030399, was opened but truncated at 100,000 of 250,301 characters and not fully mined; it adds Passiflora incarnata for this class, which is therefore NOT counted here |
| Thyroid medication | retrieval truncated at 100,000 of 157,173 characters on the first pass; a second pass read the remainder, so the whole article was covered |
| Thyroid medication | on the first pass the tables could not be read because they render as images; table rows were recovered on the second pass |
| Thyroid medication | source self-contradiction (soy), recorded not resolved: one table reports no significant change in thyroid hormone levels while another states soy causes malabsorption by adsorbing levothyroxine |
| Thyroid medication | source self-contradiction (coffee), recorded not resolved: two trials report comparable TSH whether coffee is taken 5 minutes or 1 hour after the dose, yet the same review cites those trials to advise delaying coffee by one hour |
| Thyroid medication | source self-contradiction (papaya), recorded not resolved: the mechanism is given as unknown and a recommendation said to be impossible on the evidence, while the same row lists malabsorption and advises avoiding excessive intake |
| Thyroid medication | gap: a cited reference title names tea as a cause of levothyroxine malabsorption, but the review contains no tea row and gives no tea recommendation |
| Thyroid medication | SCOPE: this review covers levothyroxine only and addresses no antithyroid drug - methimazole, carbimazole and propylthiouracil are not covered |
| Thyroid medication | ANTITHYROID DRUGS, honest empty: no published review enumerating botanical interactions with antithyroid drugs was found or opened; only consumer interaction databases surfaced, which are not published reviews and were not used |
| Thyroid medication | the review states 63 studies were included but states no count of botanical items, so the denominator 16 is the reviewer's own enumeration |
| Thyroid medication | no binomials are stated by the source for these items and none were inferred |
| Thyroid medication | non-botanical, recorded for completeness and excluded from the catalog match: vitamin C is reported to ENHANCE levothyroxine absorption, with the review recommending that concomitant ingestion be considered |
| Immunosuppressants | retrieval truncated at 100,000 of 134,114 characters on the first pass; a second pass read the remainder |
| Immunosuppressants | SCOPE: this review covers TACROLIMUS only; cyclosporine, sirolimus, mycophenolate and transplant corticosteroids are not enumerated, so this class carries no botanical list for those agents |
| Immunosuppressants | no broader immunosuppressant review was opened: the candidates found sat on hosts not reachable this run, so nothing was extracted for cyclosporine, sirolimus, mycophenolate or corticosteroids |
| Immunosuppressants | the review states no count of included articles and no count of herbs, so the denominator 13 is the reviewer's own enumeration |
| Immunosuppressants | source self-contradiction (green tea), recorded not resolved: catechins and theaflavins are listed as inhibiting CYPs and P-glycoprotein, which predicts higher exposure, while the same row gives the effect as inconclusive and the body reports a human rise alongside murine falls |
| Immunosuppressants | source self-contradiction (cranberry), recorded not resolved: the cited case reports a decrease while the review notes cranberry inhibits CYPs, which predicts the opposite |
| Immunosuppressants | contradiction recorded by the review itself (pomelo): one study contradicts the P-glycoprotein role |
| Immunosuppressants | gap (turmeric and ginger): elevation of tacrolimus is recorded for both with no active component and no mechanism, so the direction is asserted without explanation |
| Immunosuppressants | tension recorded (Schisandra sphenanthera): exacerbation of tacrolimus toxicity and a protective effect on the liver appear in the same row |
| Immunosuppressants | reference-list only, backing no claim: Ginkgo biloba, garlic oil, milk thistle, black cohosh, goldenseal, kava kava, saw palmetto, Citrus aurantium and cannabidiol appear in the bibliography but are not discussed in the body |
| Statins and lipid-lowering drugs | source self-contradiction (yarrow), recorded not resolved: the table lists yarrow as a P-glycoprotein inhibitor affecting atorvastatin while the discussion names yarrow among herbs that do not affect CYPs and may not interact significantly with statins |
| Statins and lipid-lowering drugs | source self-contradiction (pepper-rosemary), recorded not resolved: the table lists it as a CYP3A4 inhibitor affecting three statins while the discussion's non-interacting list includes pepper/rosemary |
| Statins and lipid-lowering drugs | NO HUMAN STATIN DATA IN THIS SOURCE: the article states its findings are preclinical and that the effect and severity of interactions are unknown when dealing with such preclinical findings; no effect sizes are given for any statin row |
| Statins and lipid-lowering drugs | the article states no count of herbal medicines, so the denominator 25 is the reviewer's own enumeration of species named in connection with statins |
| Statins and lipid-lowering drugs | spelling defect in the source, reproduced as printed and not corrected: the article prints Achillea millefollium |
| Statins and lipid-lowering drugs | no binomials are printed for the nine herbs named only as possibly non-interacting, so none were derived |
| Statins and lipid-lowering drugs | SCOPE LIMIT: lipid-lowering drugs other than statins are absent from this source; it names no fibrate, fenofibrate or ezetimibe. Pravastatin is described as not metabolized and therefore less affected |
| Statins and lipid-lowering drugs | a second, statin-dedicated source with human data was opened and named but NOT merged, because it enumerates polyphenol compounds rather than botanicals: Front Pharmacol 2025;16:1541871 doi:10.3389/fphar.2025.1541871. Its existence means the preclinical-only limitation is a property of the primary source, not of the literature |
| Statins and lipid-lowering drugs | the PDF was read from an institutional repository copy and could not be verified against the publisher's own record this run |
| Statins and lipid-lowering drugs | frontiersin.org refused direct retrieval through the egress proxy (403 connect_rejected) and was read through a different channel; one repository URL returned a fetch error and was abandoned without retry |
| Digoxin and cardiac glycosides | retrieval truncated at 100,000 of 168,248 characters on the first pass; a second pass read the remaining 68,248 characters, which contained only the end of the discussion, the conclusion and the reference list, so the article body is covered |
| Digoxin and cardiac glycosides | the article states no herb count; its only stated count is that 49 articles were obtained, so the denominator 50 is the reviewer's own enumeration of distinct plant-derived entries |
| Digoxin and cardiac glycosides | source self-contradiction (ginkgo), verbatim: G. biloba has no effect on the pharmacokinetic parameters of digoxin, while G. biloba extract has a significant effect |
| Digoxin and cardiac glycosides | source self-contradiction (milk thistle): the results state it significantly induces P-glycoprotein mRNA and may decrease bioavailability, while the human study it cites found no significant change |
| Digoxin and cardiac glycosides | source self-contradiction (white peony): listed as acidic and therefore lowering bioavailability, yet a decoction containing it is said to promote digoxin absorption |
| Digoxin and cardiac glycosides | source self-contradiction (schisandra): listed as acidic and lowering bioavailability, while a tablet made from Schisandra sphenanthera extract is reported to raise digoxin plasma levels |
| Digoxin and cardiac glycosides | source self-contradiction (ginseng): the review says Panax ginseng enhances the effect of digoxin, while an injection containing it is said to decrease plasma concentration and a third study found no effect |
| Digoxin and cardiac glycosides | common-name collision in the source, recorded not resolved: the same pinyin name is assigned to two species, Chaenomeles lagenaria and Carica papaya; both are carried as the review lists them |
| Digoxin and cardiac glycosides | naming inconsistency in the source: Cyperus rotundus is given two different pinyin names in one article |
| Digoxin and cardiac glycosides | source nomenclature defect, recorded not resolved: the article pairs Areca catechu with the pinyin name for garlic; neither garlic nor Allium sativum appears anywhere in the article body, so this entry should not be read as either plant without an independent check |
| Digoxin and cardiac glycosides | incomplete identifiers in the source: the rose entry is genus-only, and no binomial is printed for wheat bran, belladonna, citrus peel, citrus juices, purple grape juice, green tea or St John's wort; none were derived |
| Digoxin and cardiac glycosides | Chinese hawthorn is double-classified by the review, as lowering bioavailability and as antagonizing digoxin-induced arrhythmia; both directions are carried in one row |
| Digoxin and cardiac glycosides | several rows carry the review's own verdict that the effect on digoxin is not clear rather than a measured interaction: Dengdanhua, citrus juices, Cyperus rotundus, red sage, dong quai and ephedra |
| Digoxin and cardiac glycosides | non-botanical items are deliberately excluded and named rather than omitted: oyster shell, toad secretion products, Calculus Bovis, mother-of-pearl injections, and a list of thirty calcium-containing medicines that are predominantly mineral or animal-derived |
| Chemotherapy and oncology agents | PODOPHYLLOTOXIN, the highest-stakes check for this catalog: the terms podophyllotoxin, Podophyllum and mayapple are ABSENT from the entire text of this review, including its abstract, body, tables and full reference list. This review therefore supports no claim whatever about podophyllotoxin with etoposide or any other oncology agent, in either direction |
| Chemotherapy and oncology agents | the review's own counts, verbatim: 345 publications were retrieved and only 11 met the inclusion criteria; its abstract names six herbal products with human data |
| Chemotherapy and oncology agents | SCOPE LIMIT that caps the herb count by design: inclusion was limited to English-language studies performed in humans, so the short botanical list is a property of the inclusion criteria and is NOT evidence that other botanicals are safe with chemotherapy |
| Chemotherapy and oncology agents | source self-contradiction (milk thistle): the table says the irinotecan result is unlikely to cause clinical impact while the discussion says it can clinically influence chemotherapeutic pharmacokinetics |
| Chemotherapy and oncology agents | source self-contradiction (garlic): the table calls the docetaxel clearance decrease non-statistically significant while the text says it may pose significant risk of toxicity |
| Chemotherapy and oncology agents | source self-contradiction (St John's wort and docetaxel): the table reports a significant decrease in plasma docetaxel while the text says Cmax and half-life decreased non-significantly |
| Chemotherapy and oncology agents | spelling defect in the source, reproduced as printed: the table misspells Echinacea once |
| Chemotherapy and oncology agents | the oncology drugs covered by human data are only etoposide, docetaxel, imatinib, irinotecan and nilotinib; no platinum agent, anthracycline, antimetabolite, vinca alkaloid, other taxane or immunotherapy agent carries human herb-interaction data in this review |
| Chemotherapy and oncology agents | grapefruit juice is carried because the review groups it with herbal products, while itself noting it is mainly consumed non-medicinally |
| Chemotherapy and oncology agents | herbs mentioned only in non-chemotherapy contexts and therefore not carried: ginkgo, cranberry, grape seed, germander, black cohosh, licorice and betel nut |
| Chemotherapy and oncology agents | retrieval truncated at 100,000 of 144,094 characters on the first pass; a second pass read the remainder and added no new herb-plus-chemotherapy pairing |
| Chemotherapy and oncology agents | article-number ambiguity recorded not resolved: the DOI resolves to article 1356 while the page metadata field reads 500266 |
| Chemotherapy and oncology agents | frontiersin.org refused direct retrieval through the egress proxy (403 connect_rejected); the article was read through a different channel |
| Anticoagulants and antiplatelets (Table 3, completed retrieval) | RETRIEVAL NOW COMPLETE for this source: the remainder, characters 100,000 to 128,599, was read on a completion pass and all 26 Table 3 rows sit in it. The earlier recorded blind spot - that Table 3 may name plants not captured - is closed, and those 26 plants are the ones it named. |
| Anticoagulants and antiplatelets (Table 3, completed retrieval) | SPECIES DISCIPLINE: the ginseng row in this table is AMERICAN ginseng, Panax quinquefolius, and it runs in the DECREASED-anticoagulation direction. It is not Asian ginseng and must never be read as such. |
| Anticoagulants and antiplatelets (Table 3, completed retrieval) | source self-contradiction, recorded not resolved: the remainder states that Table 3 is the only place plants appear, yet the earlier portion names valerian in body prose, and valerian never reaches Table 3 |
| Anticoagulants and antiplatelets (Table 3, completed retrieval) | source spelling defect, reproduced as printed and not corrected: Danshen's binomial is printed Salvia milthiorriza in Table 3 and Salvia miltiorrhiza in the body text |
| Anticoagulants and antiplatelets (Table 3, completed retrieval) | source self-contradiction, recorded not resolved: soy is given both directions by the review itself |
| Anticoagulants and antiplatelets (Table 3, completed retrieval) | the per-row underlying study identifiers are UNREACHED: Table 3's caption cites its sources but those citations were not enumerated, so no row here carries its own primary identifier |
| Serotonergic drugs (Table 1, completed retrieval) | RETRIEVAL NOW COMPLETE for this source. The first pass stopped at 100,000 characters, and characters 100,000-200,000 turned out to be reference list only. The article's OWN class-assignment tables sit at 200,000-241,705, so the original cutoff had severed them entirely. A completion pass read to the end and recovered them; that is where every row above and in the arrhythmia class comes from. |
| Serotonergic drugs (Table 1, completed retrieval) | UNSUPPORTED ROW, recorded not resolved: the review assigns ginkgo a serotonergic mechanism, but every ginkgo reference it cites is titled about seizures or general toxicity, including one on fatal seizures. No serotonin source backs that row. |
| Serotonergic drugs (Table 1, completed retrieval) | the review's own grading footnote contradicts its cells: it defines Low as Level 5 and Grade D, yet six rows are printed as level 4 with grade D; it ties Grade C to Moderate, yet St John's wort is printed High with grade C; and ginkgo is printed with a grade E that the footnote never defines |
| Serotonergic drugs (Table 1, completed retrieval) | the footnote is also internally overlapping: it assigns Level 5 to both the Low and the Moderate band, so the two cannot be told apart |
| Serotonergic drugs (Table 1, completed retrieval) | cross-table contradiction: berberine is Low in the serotonergic table and Moderate in the arrhythmia table at the identical level and grade, and ginseng carries the same word at two different levels |
| Serotonergic drugs (Table 1, completed retrieval) | the table carries no active-constituents column, and it lists an opioid among turmeric's co-interactants inside a serotonergic table |
| Serotonergic drugs (Table 1, completed retrieval) | the retrieval tool enforced a 125-character ceiling on verbatim quotation, so these rows are faithful reconstructions of the table cells rather than byte-exact cell text |
| Cardiac arrhythmia and QT (Table 2, completed retrieval) | RETRIEVAL NOW COMPLETE for this source: the original 100,000-character cutoff had severed Tables 1 to 3, which sit at 200,000-241,705 and carry the article's actual class assignments. A completion pass read to the end of the article. |
| Cardiac arrhythmia and QT (Table 2, completed retrieval) | BUNDLED ROWS, stated rather than hidden: ephedra with sida, aloe with senna, and guarana with black tea, green coffee and yerba mate are each a SINGLE table row carrying one shared grade. They are split into separate botanical rows here and are not independently graded by the article. |
| Cardiac arrhythmia and QT (Table 2, completed retrieval) | QT IS NOT NAMED for five of these rows - ephedra and sida, bitter orange, yohimbe, the caffeine row and evodia. They sit in the arrhythmia table on adrenergic or ion-channel grounds instead. Only licorice, kratom, berberine, ginseng and evodia carry explicit QT or repolarization wording. |
| Cardiac arrhythmia and QT (Table 2, completed retrieval) | contradiction across the sources the review itself cites, on ephedra: one cited title reports that an ephedrine-alkaloid-free extract has no arrhythmia effect, while two others report adverse cardiovascular events with ephedra alkaloids. The review nonetheless grades ephedra High. Recorded, not resolved. |
| Cardiac arrhythmia and QT (Table 2, completed retrieval) | a second binomial is printed for the oleander row in a cited title, and a separate cited title names yellow oleander, which is a different taxon and is NOT carried as a row here |
| Cardiac arrhythmia and QT (Table 2, completed retrieval) | cross-class drug listing: the arrhythmia table names SSRIs among kratom's interacting drugs |
| Cardiac arrhythmia and QT (Table 2, completed retrieval) | the review's grading footnote contradicts its own cells here too, tying Grade D to Low while printing Moderate rows at grade D, and tying Grade C to Moderate while printing Moderate rows at level 3 |
| Cardiac arrhythmia and QT (Table 2, completed retrieval) | the retrieval tool enforced a 125-character ceiling on verbatim quotation, so these rows are faithful reconstructions of the table cells rather than byte-exact cell text |
| CYP450 and P-glycoprotein (Tables 1-7, completed retrieval) | The CYP450 retrieval that this file completes is CLOSED, and it closed by disproving its own premise. All seven tables of this review sit inside the first 100,000 characters of the article, the range an earlier pass had already read. No table appears after that point and no table is served only as a separate sub-page, so the earlier note that later tables might name further plants was a guess and is now withdrawn. Tables 1 and 2 carry no botanicals at all: they describe CYP families and clinically relevant CYP polymorphisms |
| CYP450 and P-glycoprotein (Tables 1-7, completed retrieval) | Cell prose in this pass is close paraphrase, not verbatim quotation. The working channel's reader twice refused full cell-by-cell transcription, citing a 125-character limit on quoted source text. Table captions, column headers, row counts, plant names, isoforms, directions, evidence grades and the figures carried in quotation marks are read from the page; the remaining cell wording is paraphrase and is not presented here as quotation. Anything to be published as a direct quotation from these tables must be re-opened against the source |
| CYP450 and P-glycoprotein (Tables 1-7, completed retrieval) | ASTRAGALUS MEMBRANACEUS is a third internal contradiction in this review, beyond the two already recorded, and the dual naming partly masks it: Table 4 calls the plant Huangqi and gives CYP3A4 INDUCTION by PXR activation, while Tables 5 and 7 call it Astragalus and give competitive INHIBITION of CYP2C9 and CYP3A4. The directions are opposed for the same isoforms in the same review and the source does not reconcile them |
| CYP450 and P-glycoprotein (Tables 1-7, completed retrieval) | ASHWAGANDHA, Withania somnifera, is deliberately NOT flagged for this class. Table 6 of this review records no significant inhibition, with IC50 greater than 100 micrograms per mL and evidence graded MODERATE, and calls the interaction risk low. Flagging the plant on the strength of a row that reports an absence would overstate the record. It remains flagged under the serotonergic and MSD classes on their own sources. This also places two published reviews in disagreement: the serotonin and arrhythmia review states that ashwagandha inhibits CYP3A4 and CYP2D6, while this review reports no significant inhibition. Both readings are recorded and neither is resolved here |
| CYP450 and P-glycoprotein (Tables 1-7, completed retrieval) | Four plants that this review discusses in PROSE appear in none of its seven tables: ginseng, Panax ginseng, for CYP3A4 and CYP2D6; He Shou Wu, Polygonum multiflorum, for CYP1A2, CYP2E1 and CYP3A4; milk thistle, Silybum marianum, for mild CYP3A4 inhibition; and garlic oil for CYP2E1. A table-only reading of this review therefore under-counts it. All four were already captured by the earlier pass on this same article and are already flagged |
| CYP450 and P-glycoprotein (Tables 1-7, completed retrieval) | The drug column of Table 7 is sparse: 13 of its 22 rows name no interacting drug, and one row gives the drug only as the unexpanded abbreviation TP. Table 7 also carries no dedicated CYP column, so the isoforms recorded here for that table are read from each row's own text |
| CYP450 and P-glycoprotein (Tables 1-7, completed retrieval) | Binomials this review does not state are left empty rather than derived: the species of Epimedium, of Coptidis Rhizoma and of Leonurus, and binomials for cruciferous vegetables. Glycyrrhiza is Glycyrrhiza uralensis in Table 7 but Glycyrrhiza spp. in the prose, so only the exact species named in the table is matched here and the Glycyrrhiza glabra entries in the catalog are not flagged on this source |
| CYP450 and P-glycoprotein (Tables 1-7, completed retrieval) | Three channels refused this article and were not retried: a direct request to the article page returned a proxy 403; the publisher's own copy by DOI resolver failed at its site; and a mirror at semanticscholar.org was disallowed by robots. The table sub-pages were not probed because that same channel had already served a captcha. One channel served the article, and every reading above comes from it |
Three further drug classes named as a concern in the Limits Register — sedatives and CNS depressants, thyroid medication and immunosuppressants — are covered here only where the MSD Manual table or one of the other six reviews happens to name a botanical for them. They have had no review of their own in this sweep, and statins, digoxin and chemotherapy agents have had none either. Anyone taking any of these should put the full ingredient list in front of a prescriber rather than read an absence here as clearance.